Ezrin as a prognostic indicator regulates colon adenocarinoma progression through glycolysis-Reference-Cited by-同舟云学术

Ezrin as a prognostic indicator regulates colon adenocarinoma progression through glycolysis

Published:2020-08-16 Issue:3 Volume:36 Page:710-720
ISSN:0815-9319
Container-title:Journal of Gastroenterology and Hepatology
language:en
Short-container-title:Journal of Gastroenterology and Hepatology

Author:

Wang Yixuan¹²^ORCID,Yang Yang¹²^ORCID,Wang Xinyue¹²^ORCID,Jin Tiefeng¹²,Zhu Guang¹²,Lin Zhenhua¹²

Affiliation:

1. Department of Pathology and Cancer Research Center Yanbian University Medical College Yanji China

2. Key Laboratory of the Science and Technology Department of Jilin Province Yanji China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Gastroenterology,Hepatology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/jgh.15195

Reference32 articles.

1. Adenosquamous and squamous carcinoma of the colon and upper rectum

2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

3. MicroRNA‐145 regulates the proliferation, migration and invasion of human primary colon adenocarcinoma cells by targeting MAPK1;Yang Y;Int. J. Mol. Med.,2018

4. A Novel Activating Mutation of the K-ras Gene in Human Primary Colon Adenocarcinoma

5. Altered metabolite levels in cancer: implications for tumour biology and cancer therapy

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. WTAP mediates FOXP3 mRNA stability to promote SMARCE1 expression and augment glycolysis in colon adenocarcinoma;Mammalian Genome;2022-09-29

2. Ezrin gone rogue in cancer progression and metastasis: An enticing therapeutic target;Biochimica et Biophysica Acta (BBA) - Reviews on Cancer;2022-07

3. A novel fatty acid metabolism‐related gene signature predicts the prognosis, tumor immune properties, and immunotherapy response of colon adenocarcinoma patients;FASEB BioAdvances;2022-06-13

4. Platelet CLEC2-Podoplanin Axis as a Promising Target for Oral Cancer Treatment;Frontiers in Immunology;2021-12-15